Suven Life Sciences Limited

As of June 30, 2026, Suven Life Sciences Limited carries a market capitalization of 79.30B, placing it among publicly traded companies globally. Its enterprise value stands at 79.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Suven Life Sciences Limited has 282.56M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 899.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 79.30B versus a market cap of 79.30B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 479,010.87 in revenue per employee across its workforce of 184.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Suven Life Sciences Limited's stock has gained approximately 35.80% over the past 52 weeks. The 50-day moving average sits at 335.22, while the 200-day moving average is 245.16.

Over the twelve months ended June 30, 2026, Suven Life Sciences Limited generated 88.14M in revenue and converted that into -3.52B in net income, yielding earnings per share of -15.07. EBITDA reached -3.66B, while operating income came in at -3.73B.

Over the twelve months ended June 30, 2026, Suven Life Sciences Limited posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -4,228.11 and net profit margin of -3,998.70 provide insight into operational efficiency.

Suven Life Sciences Limited's most recent stock split took place on October 17, 2022 with a 751:815 split ratio.